A single infusion of the experimental gene-editing treatment CTX310 produced sustained reductions in blood lipids in a small early-stage trial, according to results reported by CRISPR Therapeutics in August 2026.
The company said all 15 participants in the phase 1a study had completed at least one year of follow-up. In the highest-dose group, average LDL cholesterol fell 53% and triglycerides fell 48% from baseline. Those figures describe that dose group, not the average response of everyone enrolled.
Editing a liver target
CTX310 uses CRISPR-Cas9 to disrupt ANGPTL3 in the liver. The aim is to reduce the activity of a protein involved in regulating blood fats. The original trial, published in the New England Journal of Medicine in November 2025, tested escalating doses in people whose lipid levels remained high despite existing care.
Cleveland Clinic, which helped lead the research, described the study as a first-in-human test. Its early purpose was to examine safety and biological effects, rather than prove a reduction in heart attacks or strokes.
What remains to be established
The company reported no treatment-related serious adverse events in the one-year update. Earlier infusion reactions and a temporary liver-enzyme increase had been reported; a small trial cannot rule out uncommon or delayed harms.
Longer follow-up and larger studies are needed to understand the balance of benefits and risks. CTX310 remains investigational. The results do not establish a permanent cure or provide a reason for patients to stop their prescribed cholesterol treatment.
Updated Oct. 3, 2026: Adds the August 2026 one-year results while retaining the trial’s limitations.
